May 16 |
MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration
|
May 2 |
Mangoceuticals granted 180-day extension to meet minimum bid price requirement
|
May 2 |
Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement
|
Apr 25 |
Mangoceuticals acquires a global patent portfolio
|
Apr 25 |
Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care
|
Apr 23 |
Mangoceuticals files to sell 30M shares of common stock for holders
|
Apr 12 |
Mangoceuticals signs deal for initial development of erectile dysfunction products in Mexico
|
Apr 12 |
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products
|
Apr 10 |
This Mangoceuticals Insider Increased Their Holding In The Last Year
|
Mar 20 |
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
|